Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone long-term extension in mild cognitive impairment due to Alzheimer's disease
2013-004984-30Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of pioglitazone in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (2 arms), sponsored by Takeda. Started Nov 2014; status: completed.
02
Drugs
pioglitazone
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2013-004984-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004984-30.